JP2014508782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508782A5 JP2014508782A5 JP2013557943A JP2013557943A JP2014508782A5 JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5 JP 2013557943 A JP2013557943 A JP 2013557943A JP 2013557943 A JP2013557943 A JP 2013557943A JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- tumor
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims description 45
- 102000004965 antibodies Human genes 0.000 claims description 45
- 102000015694 estrogen receptors Human genes 0.000 claims description 36
- 108010038795 estrogen receptors Proteins 0.000 claims description 36
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 239000003886 aromatase inhibitor Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 16
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 10
- 229960003881 letrozole Drugs 0.000 claims description 10
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 8
- 101700025368 ERBB2 Proteins 0.000 claims description 8
- 102100016662 ERBB2 Human genes 0.000 claims description 8
- 101710037934 QRSL1 Proteins 0.000 claims description 8
- 229960000255 exemestane Drugs 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 230000001833 anti-estrogenic Effects 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 239000000328 estrogen antagonist Substances 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- 230000000865 phosphorylative Effects 0.000 claims description 7
- 229960003437 Aminoglutethimide Drugs 0.000 claims description 6
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 6
- 229950011548 FADROZOLE Drugs 0.000 claims description 6
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 6
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 229960004421 formestane Drugs 0.000 claims description 6
- 150000002596 lactones Chemical class 0.000 claims description 6
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
- 229960002932 anastrozole Drugs 0.000 claims description 5
- -1 lasofoxone Chemical compound 0.000 claims description 5
- 230000001404 mediated Effects 0.000 claims description 5
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 4
- TXUZVZSFRXZGTL-QPLCGJKRSA-N Afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 claims description 4
- MCGDSOGUHLTADD-UHFFFAOYSA-N Arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 claims description 4
- 229950005529 Arzoxifene Drugs 0.000 claims description 4
- 229960002258 Fulvestrant Drugs 0.000 claims description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004622 Raloxifene Drugs 0.000 claims description 4
- 229960001603 Tamoxifen Drugs 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 4
- 210000004027 cells Anatomy 0.000 claims description 4
- 229960005026 toremifene Drugs 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 210000000481 Breast Anatomy 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 210000004881 tumor cells Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 11
- 229940088597 Hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 6
- HKVAMNSJSFKALM-XJFKSLPYSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-XJFKSLPYSA-N 0.000 description 4
- 229960005167 everolimus Drugs 0.000 description 4
- 229940121647 EGFR inhibitors Drugs 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N Deforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 108010042024 pertuzumab Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960001302 ridaforolimus Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- KFHMLBXBRCITHF-UHFFFAOYSA-N 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC1=CC=CC(Br)=C1 KFHMLBXBRCITHF-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- 229960001686 Afatinib Drugs 0.000 description 1
- 240000002254 Ananas comosus Species 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 229940045988 antineoplastic drugs Protein kinase inhibitors Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161451848P | 2011-03-11 | 2011-03-11 | |
US61/451,848 | 2011-03-11 | ||
US201261604281P | 2012-02-28 | 2012-02-28 | |
US61/604,281 | 2012-02-28 | ||
PCT/US2012/028792 WO2012125573A2 (en) | 2011-03-11 | 2012-03-12 | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014508782A JP2014508782A (ja) | 2014-04-10 |
JP2014508782A5 true JP2014508782A5 (US07794700-20100914-C00152.png) | 2015-04-30 |
Family
ID=45894680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013557943A Pending JP2014508782A (ja) | 2011-03-11 | 2012-03-12 | ホルモン不応性乳癌の治療におけるegfrファミリー受容体の阻害剤の使用 |
Country Status (12)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
EP2859893A1 (en) * | 2010-03-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
WO2013164689A2 (en) | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CA2941030A1 (en) | 2014-02-28 | 2015-09-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
CN104208069A (zh) | 2014-05-08 | 2014-12-17 | 上海市计划生育科学研究所 | 双炔失碳酯组合物和疾病治疗方法 |
JP2018513155A (ja) | 2015-04-17 | 2018-05-24 | メリマック ファーマシューティカルズ インコーポレーティッド | セリバンツマブを用いた併用療法 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
ITUB20160828A1 (it) * | 2016-02-18 | 2017-08-18 | Univ Degli Studi Genova | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro |
CA3011949A1 (en) * | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
CA3040266A1 (en) | 2016-10-11 | 2018-05-24 | Duke University | Lasofoxifene treatment of er+ breast cancer |
JP6899504B2 (ja) * | 2017-01-10 | 2021-07-07 | ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド | 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法 |
MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
ES2951864T3 (es) * | 2017-05-17 | 2023-10-25 | Merus Nv | Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama |
MA49846A (fr) | 2017-08-09 | 2020-06-17 | Merus Nv | Anticorps qui se lient à l'egfr et à cmet |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
WO2022078490A1 (zh) * | 2020-10-15 | 2022-04-21 | 上海翰森生物医药科技有限公司 | 抗erbb3抗体或其抗原结合片段及其医药用途 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU6113396A (en) | 1995-06-14 | 1997-01-15 | Regents Of The University Of California, The | Novel high affinity human antibodies to tumor antigens |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7638302B2 (en) | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
ES2582386T3 (es) | 2007-03-01 | 2016-09-12 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
KR20100024410A (ko) | 2007-05-11 | 2010-03-05 | 엔즌 파마슈티칼스, 인코포레이티드 | Her3 조절용 rna 길항제 화합물 |
KR20110008086A (ko) * | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
US8927694B2 (en) * | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
EP2859893A1 (en) * | 2010-03-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
EA201390085A1 (ru) * | 2010-07-09 | 2013-06-28 | Экселиксис, Инк. | Композиции ингибиторов киназ для лечения рака |
-
2012
- 2012-03-12 JP JP2013557943A patent/JP2014508782A/ja active Pending
- 2012-03-12 KR KR1020137026392A patent/KR20140044796A/ko not_active Application Discontinuation
- 2012-03-12 US US14/004,598 patent/US20140134170A1/en not_active Abandoned
- 2012-03-12 MX MX2013010379A patent/MX2013010379A/es unknown
- 2012-03-12 EP EP12711080.7A patent/EP2683741A2/en not_active Withdrawn
- 2012-03-12 EA EA201300996A patent/EA201300996A1/ru unknown
- 2012-03-12 AU AU2012229147A patent/AU2012229147B2/en not_active Ceased
- 2012-03-12 CA CA2828075A patent/CA2828075A1/en not_active Abandoned
- 2012-03-12 BR BR112013022882A patent/BR112013022882A2/pt not_active IP Right Cessation
- 2012-03-12 WO PCT/US2012/028792 patent/WO2012125573A2/en active Application Filing
- 2012-03-12 CN CN201280012969.XA patent/CN103562226A/zh active Pending
- 2012-03-12 SG SG2013062856A patent/SG192844A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014508782A5 (US07794700-20100914-C00152.png) | ||
US20190119401A1 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
Prenen et al. | Role of targeted agents in metastatic colorectal cancer | |
AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
JP6829193B2 (ja) | がんを治療するための単独または併用療法におけるccr5拮抗剤の使用 | |
EP2686015A2 (en) | Overcoming resistance to erbb pathway inhibitors | |
JP2023145689A (ja) | Her2陽性がんの処置 | |
EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
JP2019517498A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗pd−1抗体 | |
JP2017534574A (ja) | チロシンキナーゼ阻害薬(tki)に耐性のがんを処置するための組成物および方法 | |
AU2010236818B2 (en) | Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors | |
JP2023502585A (ja) | 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害 | |
Ito et al. | Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? | |
WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
JP6712226B2 (ja) | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子(igf)受容体アンタゴニストを用いる癌治療 | |
JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
JP2024511995A (ja) | がん治療における第一選択療法としてのsEphB4-HSA融合タンパク質の使用 | |
WO2023230429A1 (en) | Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody | |
KR20240093915A (ko) | 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 | |
TWI500630B (zh) | 具有細胞生長抑制功效之表皮生長因子受體(egfr)抑制劑類及彼等於腫瘤治療上之用途 | |
NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
Garca‐Saénz et al. | Pertuzumab (Perjeta®) |